The Efficacy and Mechanism of Xuefu Zhuyu Decoction Combined with Tenofovir Dipyrfurate Fumarate Tablets in The Treatment of Liver Depression and Blood Stasis Type Hepatitis B Cirrhosis

Background: Cirrhosis is a chronic progressive liver disease. Hepatocyte injury leads to liver dysfunction. At present, antiviral drugs are mainly used to inhibit the replication of hepatitis virus to block liver fibrosis. Tenofovir disoproxil fumarate is a novel nucleotide reverse transcriptase inhibitor, which can eliminate hepatitis B virus and control the deterioration of chronic hepatitis B. Objective To investigate the efficacy and mechanism of Xuefu Zhuyu Decoction combined with tenofovir disoproxil fumarate tablets in the treatment of hepatitis B cirrhosis of liver depression and blood stasis. Methods A total of 150 patients with hepatitis B cirrhosis who were treated in our hospital from January 2019 to June 2021 with the dialectical type of "liver stagnation and blood stasis" were selected and divided into groups according to their treatment plan. 75 cases in the control group were given Fu Tenofovir disoproxil marate tablets were treated, and 75 patients in the observation group were treated with Xuefu Zhuyu Decoction combined with tenofovir disoproxil fumarate tablets. Count the total effective rates and adverse reactions of the two groups, record the scores of TCM syndromes, liver hemodynamics, fibrosis, liver function, hepatitis B virus deoxyribonucleic acid (HBV-DNA), MMP1, TIMP1, TIMP1/MMP1 changes. Results The curative effect of the observation group was higher than that of the control group, which was statistically significant (P<0.05). Compared with before treatment, the portal vein flow rate (PW) and intrahepatic circulation time (HV-HA) of the two groups increased (P<0.05), the portal vein congestion index (PV-CI) decreased (P<0.05), and the portal vein diameter (PVD) Compared with before treatment, the difference was not statistically significant (P>0.05). After treatment, PW and HV-HA in the observation group were higher than those in the control group (P<0.05), and PV<I was lower than that in the control group (P<0.05). Compared with the control group, the difference was not statistically significant (P>0.05). Compared with before treatment, the scores of the two groups of chest and hypothermia distended, abdominal distension, mental fatigue, depression, irritability, and amitrati decreased (P<0.05). The scores of TCM syndromes of the observation group were lower than those of the control group (P<0.05). P<0.05). Compared with before treatment, the two groups of matrix metalloproteinase 1 (MMP1) increased (P<0.05), laminin (LV), type IV collagen (IV-C), type III procollagen (PCIHT, hyaluronic acid (P<0.05) HA), tissue inhibitor of matrix metalloproteinase 1 (TIMP1), TIMP1/MMP1, alanine aminotransferase (ALT), aspartate aminotransferase (AST), HBV-DNA decreased (P<0.05), observe After treatment, MMP1 in the group was higher than that in the control group (P<0.05), and fibrosis indexes, liver function indexes, TIMP1, TIMP1/MMP1, and HBV-DNA were lower than those in the control group (P<0.05). The adverse reactions between the two groups were not statistically significant (P>0.05). Conclusion Xuefu Zhuyu Decoction combined with tenofovir disoproxil fumarate tablets is effective in treating hepatitis B cirrhosis of liver depression and blood stasis, and its mechanism may be related to improving liver hemodynamics, regulating fibrosis, liver function and other indicators related.